

Appendix: Tables

1.	Sales January to March 2021 and 2020	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2021 vs. Q1 2020	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2021 vs. Q1 2020.....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2021 vs. Q1 2020	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*	11

1. Sales January to March 2021 and 2020

CHF millions	Three months ended 31 March		% change	
	2021	2020	At CER	In CHF
Pharmaceuticals Division	10,600	12,262	-9	-14
United States	5,292	6,616	-14	-20
Europe	2,175	2,264	-6	-4
Japan	852	948	-7	-10
International*	2,281	2,434	0	-6
Diagnostics Division	4,330	2,881	55	50
Roche Group	14,930	15,143	3	-1

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020

CHF millions	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020
Pharmaceuticals Division	12,262	7	10,940	-6	11,115	-4	10,215	-7	10,600	-9
United States	6,616	3	5,848	-10	5,925	-5	5,258	-13	5,292	-14
Europe	2,264	14	1,926	-3	2,078	2	1,930	-8	2,175	-6
Japan	948	3	960	-7	894	-13	963	-5	852	-7
International*	2,434	16	2,206	5	2,218	-2	2,064	11	2,281	0
Diagnostics Division	2,881	5	3,198	2	3,583	18	4,129	28	4,330	55
Roche Group	15,143	7	14,138	-4	14,698	1	14,344	1	14,930	3

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2021 vs. Q1 2020

Top-selling pharmaceuticals January - March 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,226	16	914	9	217	37	-	-	95	77
Perjeta	988	2	360	-2	301	-3	64	-11	263	23
Avastin	863	-40	287	-48	138	-68	161	-8	277	-4
Actemra/RoActemra	779	22	305	10	239	12	84	-2	151	134
Tecentriq	775	26	395	13	168	14	120	82	92	84
Herceptin	755	-35	191	-57	146	-25	22	-43	396	-16
MabThera/Rituxan	705	-46	426	-53	69	-45	10	-37	200	-23
Hemlibra	661	33	398	21	136	71	79	11	48	214
Kadcyla	478	17	200	5	167	24	27	54	84	28
Xolair	409	-6	409	-6	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2021 vs. Q1 2020

New products January - March 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	60	-13	38	-15	15	-15	-	-	7	3
Perjeta	988	2	360	-2	301	-3	64	-11	263	23
Kadcyla	478	17	200	5	167	24	27	54	84	28
Gazyva/Gazyvaro	155	-2	74	0	51	-11	14	1	16	21
Esbriet	256	-8	173	-8	69	-10	-	-	14	0
Cotellic	10	-25	3	14	5	-33	-	-	2	-35
Alecensa	298	14	77	-2	74	11	55	8	92	44
Tecentriq	775	26	395	13	168	14	120	82	92	84
Ocrevus	1,226	16	914	9	217	37	-	-	95	77
Hemlibra	661	33	398	21	136	71	79	11	48	214
Xofluza	-	-100	-	-100	-	-	-	-	-	-100
Polivy	43	18	19	-25	22	111	-	-	2	**
Rozlytrek	9	187	6	113	1	**	1	**	1	**
Phesgo	29	-	20	-	7	-	-	-	2	-
Enspryng	14	-	2	-	-	-	12	-	-	-
Evrysdi	80	-	79	-	-	-	-	-	1	-
Casirivimab/imdevimab	166	-	-	-	166	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2021 vs. Q1 2020

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,226	16	914	9	217	37	-	-	95	77
Perjeta	988	2	360	-2	301	-3	64	-11	263	23
Avastin	863	-40	287	-48	138	-68	161	-8	277	-4
Actemra/RoActemra	779	22	305	10	239	12	84	-2	151	134
Tecentriq	775	26	395	13	168	14	120	82	92	84
Herceptin	755	-35	191	-57	146	-25	22	-43	396	-16
MabThera/Rituxan	705	-46	426	-53	69	-45	10	-37	200	-23
Hemlibra	661	33	398	21	136	71	79	11	48	214
Kadcyla	478	17	200	5	167	24	27	54	84	28
Xolair	409	-6	409	-6	-	-	-	-	-	-
Lucentis	337	-7	337	-7	-	-	-	-	-	-
Activase/TNKase	304	-17	291	-17	-	-	-	-	13	-10
Alecensa	298	14	77	-2	74	11	55	8	92	44
Esbriet	256	-8	173	-8	69	-10	-	-	14	0
Casirivimab/imdevimab	166	-	-	-	166	-	-	-	-	-
Gazyva	155	-2	74	0	51	-11	14	1	16	21
CellCept	154	-5	11	-31	38	-22	17	-9	88	11
Pulmozyme	139	-23	85	-28	30	-20	-	-	24	3
Madopar	108	13	-	-	26	-13	-	-	82	25
Mircera	105	-13	-	-	13	-23	29	-18	63	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020
Ocrevus	1,112	38	964	12	1,198	37	1,052	10	1,226	16
Perjeta	1,011	22	930	12	988	17	954	20	988	2
Avastin	1,497	-13	1,338	-24	1,188	-30	969	-35	863	-40
Actemra/RoActemra	666	30	795	40	673	27	724	29	779	22
Tecentriq	644	99	653	54	718	49	723	35	775	26
Herceptin	1,207	-24	993	-33	879	-38	653	-43	755	-35
MabThera/Rituxan	1,389	-15	1,051	-32	1,003	-33	780	-43	705	-46
Hemlibra	521	146	482	59	572	57	615	45	661	33
Kadcyla	428	55	409	26	458	33	450	26	478	17
Xolair	468	3	490	1	493	3	453	3	409	-6
Lucentis	387	-13	341	-25	392	-5	324	-22	337	-7
Activase/TNKase	390	11	301	-3	314	1	316	11	304	-17
Alecensa	268	43	272	27	301	37	319	54	298	14
Esbriet	292	22	274	2	278	5	264	-9	256	-8
Casirivimab/imdevimab	-	-	-	-	-	-	-	-	166	-
Gazyva	165	49	145	23	162	15	160	6	155	-2
CellCept	166	7	148	-2	148	-11	144	-1	154	-5
Pulmozyme	191	10	161	-10	148	-16	142	-17	139	-23
Madopar	98	5	96	23	86	2	81	4	108	13
Mircera	126	-8	125	-7	118	-26	101	-24	105	-13

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020
Ocrevus	156	79	141	26	193	56	184	20	217	37
Perjeta	307	21	260	1	291	13	292	4	301	-3
Avastin	423	-3	373	-13	286	-33	170	-61	138	-68
Actemra/RoActemra	209	27	173	2	186	10	215	24	239	12
Tecentriq	145	169	137	90	155	72	139	18	168	14
Herceptin	193	-32	168	-33	161	-30	143	-31	146	-25
MabThera/Rituxan	123	-24	79	-44	102	-29	75	-36	69	-45
Hemlibra	78	216	68	92	115	171	112	99	136	71
Kadcyla	132	43	125	26	147	39	156	34	167	24
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Alecensa	66	51	59	27	68	22	71	22	74	11
Esbriet	74	28	60	-3	64	-2	68	2	69	-10
Casirivimab/imdevimab	-	-	-	-	-	-	-	-	166	-
Gazyva	56	57	45	13	54	26	56	15	51	-11
CellCept	48	15	32	-20	39	-8	38	-10	38	-22
Pulmozyme	37	12	31	0	31	3	34	4	30	-20
Madopar	29	13	24	-11	28	2	28	-2	26	-13
Mircera	17	6	14	-13	14	-14	13	-17	13	-23

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	74	49	75	11	70	-9	75	0	64	-11
Avastin	181	-5	182	-19	171	-25	183	-7	161	-8
Actemra/RoActemra	89	6	92	-8	86	-15	99	1	84	-2
Tecentriq	69	111	79	94	77	62	105	75	120	82
Herceptin	40	-26	37	-45	32	-46	31	-43	22	-43
MabThera/Rituxan	17	-39	16	-45	15	-38	16	-34	10	-37
Hemlibra	74	207	77	36	76	13	86	15	79	11
Kadcyla	18	3	23	3	22	7	27	41	27	54
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Alecensa	53	15	62	8	58	8	67	29	55	8
Esbriet	-	-	-	-	-	-	-	-	-	-
Casirivimab/imdevimab	-	-	-	-	-	-	-	-	-	-
Gazyva	15	95	21	65	15	-36	18	-9	14	1
CellCept	19	0	21	-6	19	-3	21	1	17	-9
Pulmozyme	-	-	-	-	1	40	-	-	-	-
Madopar	-	-	-	-	-	-	-	-	-	-
Mircera	37	-17	38	-29	39	-20	40	-18	29	-18

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2020	% change vs. Q1 2019	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020
Ocrevus	58	119	50	43	66	74	70	55	95	77
Perjeta	235	83	220	50	259	52	249	135	263	23
Avastin	307	5	312	-6	299	-14	310	8	277	-4
Actemra/RoActemra	72	27	134	123	151	209	140	114	151	134
Tecentriq	54	101	69	120	64	74	79	86	92	84
Herceptin	499	4	415	-14	373	-28	284	-29	396	-16
MabThera/Rituxan	276	-9	236	-25	214	-30	190	-24	200	-23
Hemlibra	16	**	26	319	25	58	49	325	48	214
Kadcyla	74	63	61	12	76	30	77	50	84	28
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	14	27	13	4	12	-5	14	1	13	-10
Alecensa	65	97	67	107	86	141	95	**	92	44
Esbriet	16	23	14	3	14	5	10	-9	14	0
Casirivimab/imdevimab	-	-	-	-	-	-	-	-	-	-
Gazyva	15	7	14	16	15	5	15	-1	16	21
CellCept	81	11	81	18	75	-10	70	4	88	11
Pulmozyme	26	8	14	-25	17	-6	14	-7	24	3
Madopar	69	2	72	40	58	2	53	6	82	25
Mircera	72	-6	73	13	65	-31	48	-30	63	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%